Lanean...
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
BACKGROUND: Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma i...
Gorde:
| Argitaratua izan da: | Gynecol Oncol Res Pract |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6098839/ https://ncbi.nlm.nih.gov/pubmed/30147940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40661-018-0063-3 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|